NCT00352196View on ClinicalTrials.gov

Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study

PHASE4CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Asperger's Disorder
Interventions
DRUG

Risperidone

12 weeks of treatment with risperidone 0.25 to 11 mg per day.

OTHER

Magnetic Resonance Spectroscopy

Subjects will receive a standard MRS to assess the concentrations and ratios of brain metabolites N-acetylaspartate, creatine, phosphocreatine, and choline.

Trial Locations (1)

30912-3800

Medical College of Georgia, Dept. of Psychiatry, Augusta

All Listed Sponsors
collaborator

Ortho-McNeil Janssen Scientific Affairs, LLC

INDUSTRY

lead

Augusta University

OTHER

NCT00352196 - Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study | Biotech Hunter | Biotech Hunter